Wat is de prijs voor Alimera Sciences, Inc. (ALIM)

Het prijs van Alimera Sciences, Inc. (ALIM) is $5.54

Wat is de marktkapitalisatie voor Alimera Sciences, Inc. (ALIM)

Marktkapitalisatie voorAlimera Sciences, Inc. (ALIM) is $38.76M

Alimera Sciences, Inc. (ALIM) Aandelensplitsingen

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
2019-11-15	1:15	x0.066666666666667	x0.066666666666667

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

2019-11-15

1:15

x0.066666666666667

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land